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We have previously demonstrated (1-4) that the incubation of human periph- 
eral blood lymphocytes or murine splenocytes in the lymphokine, interleukin 2 
(IL-2)  1,  leads  to  the  generation of cells  capable  of lysing fresh  syngeneic or 
autologous tumors in short-term chromium-release assays. These lytic cells have 
been  termed lymphokine-activated killer (LAK) cells,  and they exhibit broad 
lytic specificity for a variety of fresh tumors, but they do not lyse fresh normal 
cells. Recombinant IL-2 produced in E. coli and purified to apparent homogeneity 
is  highly effective  in  generating  LAK  cells  from  both  human  and  murine 
lymphocytes (5).  We  have  recently demonstrated (6,  7)  that  the  intravenous 
injection of LAK cells in conjunction with recombinant IL-2 can mediate the 
regression of established pulmonary metastases from a  variety of sarcomas, as 
well as from the B 16 melanoma. 
Because recombinant IL-2 is  capable  of efficiently generating LAK cells  in 
vitro, and because the systemic administration of LAK cells has potent antitumor 
activities,  we  have  studied  the  possible  use  of high-dose  recombinant  IL-2 
administered directly to tumor-bearing mice, aiming to generate LAK cells in 
vivo and mediate tumor regression.  In these studies,  we have shown that the 
systemic administration of high doses of recombinant IL-2 leads to the generation 
of LAK cells in  the spleens of recipient mice and mediates the regression of 
established pulmonary metastases and subcutaneous implants from a variety of 
tumors. Tumor regression appears  to be mediated by endogenously activated 
lymphocytes, presumably LAK cells, present at the tumor site and in the organs 
of mice receiving high-dose recombinant IL-2. 
Materials and Methods 
Animals.  Female  C57BL/6  mice  were  obtained  from  the  Small Animal  Section, 
Veterinary Resources  Branch, National Cancer  Institute, Bethesda, MD, or from The 
Jackson  Laboratory, Bar  Harbor,  ME.  All  mice  were  12-16  wk  old  when  used  in 
experiments. 
Tumors.  The MCA-105 and MCA-106 tumors were induced in our laboratory  by 
1  Abbreviations used in this paper:  HBSS,  Hank's  balanced salt solution; IL-2,  interleukin  2; LAK, 
lymphokine-activated  killer cells; NK, natural killer cells. 
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intramuscular  injection  of 0.1  ml  of 0.1%  3-methyicholanthrene  in  sesame  oil.  These 
tumors were serially transplanted into syngeneic C57BL/6 mice by intramuscular injection 
of a tumor cell suspension prepared by mechanical means. At the first transplant genera- 
tion, multiple vials of tumor were cryopreserved. For all experiments reported here, the 
tumor was used within the first seven transplant generations. When a tumor reached the 
seventh  transplant  generation,  a  new  vial  from  the  first  generation  was  thawed  and 
transplanted.  These  tumors  grew  progressively,  and  were  invariably  fatal  in  normal 
syngeneic mice. 
The B16 melanoma is a long-transplanted tumor syngeneic to C57BL/6 mice. Multiple 
vials of tumor from a  single tissue culture passage were cryopreserved, and a  fresh vial 
was thawed for each experiment. 
Preparation  of Single-cell Suspensions from  Solid  Tumor.  Intramuscular  tumors  were 
excised when  they reached  1-1.5  cm in diameter,  and  were dissected  free of necrotic 
tumor and connective tissue. The remaining tumor was minced into 2 mm fragments and 
digested,  with  constant  stirring,  in  40  ml  of Hank's  Balanced  Salt  Solution  (HBSS) 
containing 4 mg deoxyribonuclease, 40 mg collagenase, and 100 U hyaluronidase (Sigma 
Chemical Co., St.  Louis, MO) for 3 h  at room temperature,  as previously described (7). 
The supernatant  cell suspension was then harvested,  washed three  times in HBSS, and 
adjusted to the desired concentration. 
The B 16 melanoma was thawed and placed in culture for ~ 18 h before harvesting the 
cell  monolayer  using  0.25%  trypsin  in  Dulbecco's  phosphate-buffered  saline  without 
calcium and magnesium. The cell suspension was washed three times, and suspended in 
HBSS at the desired cell concentration. 
Tumor  Therapy Protocol for Pulmonary Metastases.  2  ×  105-3  ×  105  tumor cells,  in 
single-cell suspension in HBSS, were injected, in 1 ml volumes, into the tail veins of mice. 
After 3 d, micrometastases were present in the lungs and were invading into the pulmonary 
alveoli. By 10 d after tumor cell injection, grossly visible metastases were present on the 
surface of the lung. At 3 or 10 d after tumor cell injection, therapy with intraperitoneally 
injected  IL-2 was begun. At  15-18 d  after tumor cell injection,  mice were ear-tagged, 
randomized, and killed. The lungs were removed by opening the thoracic cavity, injecting 
a  15%  solution of India ink into the  trachea,  and  "bleaching"  with  Fekette's  solution, 
using a  technique described previously (8).  The white tumor nodules in the black lung 
were counted without knowledge of the treatment received. After all data were recorded 
the  mice and  their  tissues  were identified.  All treatment  groups contained at  least  five 
mice. 
Tumor  Therapy Protocol for Subcutaneous Tumor.  2  ×  104  MCA-105  tumor cells,  in 
single-cell suspension  in  HBSS,  were injected,  in  0.05  ml  volumes,  in the  belly skin  of 
mice.  The  tumor was injected  as superficially as possible,  raising a  "bleb"  in  the  skin. 
Animals were examined three times weekly, and perpendicular diameters were measured 
with a vernier caliper. 
1L-2.  The gene for IL-2 was isolated from a high-producer Jurkat cell line,  inserted 
into E. coli, and expressed at high levels, as previously described (5). The IL-2 was purified 
to apparent homogeneity, as demonstrated by the presence of a single band of ~ 15,000 
tool  wt.  The  recombinant  IL-2  for  these  studies  was  kindly  supplied  by  the  Cetus 
Corporation,  Emeryville, CA.  IL-2 activity was measured  using a  standard bioassay, as 
previously described (9).  The endotoxin level in purified preparations was <0.1  ng/106 
U  IL-2, as measured by a standard Limulus assay. 
Assessment of LAK Activity in Splenocytes.  Spleens  were  excised  and  dissociated  into 
single-cell suspensions in HBSS by pressing with the blunt end of a  10-ml plastic syringe 
plunger. Erythrocytes were iysed in ammonium chloride-potassium lysing buffer (Media 
Production  Section,  NIH)  and  were  washed  three  times  in  HBSS.  The  resultant  cell 
suspension  was  filtered  through  a  double  layer  of no.  100  nylon  mesh  (Nitex),  and 
resuspended  in  medium  for assay of cytotoxicity against  fresh  MCA sarcoma cells  in a 
standard 4-h chromium-release assay. 
Statistical Analysis.  Statistical analyses were performed using a Wilcoxon rank sum test 
(10). All P values reported are two-sided values. ROSENBERG  ET  AL. 
TABLE  I 
Induction of LAK Activity in Spleens of  Mice Treated with 
Recombinant IL-2 
1L-2* 
Lyric activity against MCA-102 
E:T* 
100:1  20:1 
U  %! 
0  -1  +2  -3+3 
75,000  14 ±  1  -2  ±  1 
100,000  17 ±  2  1 ±  2 
150,000  19 ±  1  9 ±  1 
200,000  21  ±  4  11 ±  1 
400,000  32 ±  2  16 ±  4 
*  IL-2 was administered for 5 d  in 0.5 ml i.p., approximately every 8  h. 
* Effector/target ratio in 4-h 51Cr-release assay. 
t  Percent lysis ±  SEM. 
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Results 
Systemic  Administration  of  Recombinant  IL-2  Generated  LAK  Cells  in  the 
Spleen.  To test the ability of recombinant  IL-2 to induce LAK cell activity in 
vivo, mice were injected with varying doses of IL-2 approximately every 8 h for 
5 d.  The  IL-2 was given by intraperitoneal  injection in 0.5 ml  HBSS, and was 
injected at approximately 8:00 am, 4:00 pro, and  11:00 pm of each day. On the 
morning  of the  sixth  day,  mice were  killed,  and  LAK activity in  spleens  was 
assessed using a fresh MCA sarcoma single-cell suspension as target. As shown in 
Table I, increasing doses of recombinant  IL-2 resulted in a  successive increase 
in the lyric activity in the spleen against fresh sarcoma cells. 
Systemic Administration of Recombinant IL-2 Reduced the Number of Established  3- 
d Pulmonary Metastases.  3 d after the intravenous injection of MCA-105 tumor 
cells in the tail vein, mice were treated with varying doses of recombinant IL-2 
in 0.5 mi i.p., approximately every 8 h for 5 d. Mice were killed at 15 d, and the 
number of pulmonary  metastases in the lung was determined.  A  characteristic 
experiment is shown in Fig. 1. Recombinant IL-2 at a dose of 50,000 or 100,000 
U  was capable of significantly  reducing  the number  of pulmonary  metastases. 
Mice receiving either  HBSS alone,  or 5,000 or 20,000  U  of IL-2  had a  mean 
number of metastases of >250, 212, and 214, respectively (no significant differ- 
ences between these groups).  Mice receiving 50,000 or  100,000 U  of IL-2 had 
a  mean  of  19  and  61  metastases,  respectively  (P  =  0.002  and  P  =  0.003, 
respectively, compared to HBSS group). 
The ability of high-dose recombinant I L-2 to reduce the number of established 
3-d pulmonary metastases was highly reproducible. The results of 36 consecutive 
experiments,  using doses between 3,000 and  170,000  U  of recombinant  IE-2 
administered three times daily for 5 d is shown in Fig. 2. The percent reduction 
in  pulmonary  metastases  of mice  treated  with  IL-2  at  three  dosage  ranges  is 
compared to mice treated with HBSS alone.  Mice receiving between 3,000 and 
8,000 U  of IL-2 intraperitoneally  three times daily had 5.7 +  5.0% (mean +SE) 
reductions  in pulmonary  metastases,  mice receiving 20,000-50,000  U  of IL-2 1172  IL-2-INDUCED  TUMOR  REGRESSION 
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FIGURE  1.  Treatment of day  3  pulmonary metastases with recombinant IL-2.  3  d  after 
intravenous injection of 3  x  105  MCA-105 sarcoma cells, mice began therapy with varying 
doses of recombinant I L-2 administered intraperitoneally three times daily for 5 d. At day 15, 
mice were killed and the number of pulmonary nodules was determined. Each dot represents 
the measurement of a  single mouse. Doses of 50,000-100,000  U  IL-2 administered in this 
schedule significantly reduced the number of pulmonary metastases compared to mice receiv- 
ing no IL-2 (P =  0.002 and P =  0.003, respectively). 
had  22.2  -+  9.2%  reductions,  and  mice  receiving  100,000-170,000  U  IL-2 
experienced 79.5 + 7.3% reductions in pulmonary metastases. The dosage range 
of 20,000-50,000  U IL-2 appeared to be on the threshold of mediating antitu- 
mor effects, and although significant variation was seen in different experiments 
at this dose range, the use of 100,000 U or more consistently reduced pulmonary 
metastases (9 of 10 experiments). No statistically significant increase in metastases 
due to IL-2 therapy was seen in any experiment. 
Other tumors, treated beginning 3 d  after tumor injection, were also suscep- 
tible to the therapeutic effects of recombinant IL-2. Representative experiments 
with  the  MCA-106  sarcoma  and  the  B16  melanoma  are  shown  in  Fig.  3. 
Statistically significant reductions in the number of pulmonary metastases were 
seen  in  both of these tumor models when  100,000  U  IL-2 was administered 
three  times  a  day  for  5  d,  starting  on  day  3  (P  =  0.006  and  P  =  0.005, 
respectively). 
Reduction  of Established  lO-d Pulmonary Metastases  in Mice  by  Treatment with 
Recombinant IL-2.  In all experiments presented thus far, treatment was initiated 
on  day 3  after tumor cell  injection, when no  grossly visible metastases were 
present in the lungs. By  10  d  after tumor cell injection, grossly visible  tumor 
metastases could be seen on the surface of the lung, and large nodules could be 
seen  in  histologic sections of lung.  A  series  of experiments were  conducted, 
initiating therapy 10 d after tumor cell injection and continuing treatment three ROSENBERG  ET  AL.  1173 
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FIGURE 2.  Results of 36 consecutive experiments evaluating the ability of varying doses of 
recombinant IL-2  to  reduce day  3  pulmonary  metastases. Each  dot represents a  separate 
experimental measurement in which mice receiving IL-2 were compared to mice treated with 
HBSS alone.  Therapy  with varying doses of IL-2  was initiated 3  d  after the intravenous 
injection of MCA-105 sarcoma cells. IL-2 was administered intraperitoneally approximately 
every  8  h  for  5  d.  Doses of  100,000-170,000  U  IL-2  significantly reduced  pulmonary 
metastases in 9 of 10 experiments. 
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FIGURE 3.  Reduction of pulmonary metastases of the MCA-106 sarcoma (left) and the B 16 
melanoma (right)  by administration of recombinant IL-2.  3  d  after intravenous injection of 
either  MCA-106  sarcoma  or B16  melanoma cells, therapy  was initiated with  100,000  U 
recombinant IL-2 given intraperitoneally approximately every 8 h  for 5 d. On day 15, mice 
were killed and pulmonary nodules were counted. Each dot represents the measurement of a 
single mouse. A significant reduction in the number of pulmonary metastases was seen in the 
treatment of both tumors when IL-2 was administered (P =  0.006 for the MCA-106 sarcoma, 
and P =  0.005 for the B16 melanoma). 1174  IL-2-INDUCED  TUMOR  REGRESSION 
TABLE II 
Reduction of Established ( l O-d) Pulmonary Metastases in Mice by Treatment with 
Recombinant  IL-2 
I L-2*  Number of metastases  Mean  P* 
U 
Exp.  1 
0  >250,  >250,  >250,  >250,  >250  >250  -- 
1,000  >250,  >250,  150,  138,  103  178  0.10 
4,000  >250,  >250,  >250,  113,  78  188  0.18 
20,000  48,  37,  24,  5,  5  24  0.007 
100,000  33,  19,  13,  11,  3  16  0.008 
Exp. 2 
0  >250,  >250,  >250,  197,  189  227  -- 
1,000  >250,  >250,  >250,  164,  126  208  0.72 
6,000  >250,  >250,  207,  147,  2  171  0.50 
20,000  >250,  22,  5,  2,  0  56  0.07 
100,000  32,  6,  4,  1,  0  9  0.01 
* 1L-2 was administered in 0.5 ml i.p., three times daily for 5 d, starting 10 d after tumor injection. 
* Wilcoxon rank sum test of group receiving IL-2 compared to group receiving no IL-2 (two-sided). 
times a  day for 5 d.  In these experiments, mice were usually killed on the  18th 
day after  tumor  cell  injection,  and  the  number  of pulmonary  metastases  was 
determined. Two representative dose-titration experiments are shown in Table 
II.  In  exp.  1,  a  statistically  significant reduction  in  pulmonary metastases  was 
seen at 20,000 U  (mean =  24) and  100,000 units (mean =  16) of IL-2 adminis- 
tered three  times  daily for  5  d,  compared  to  mice  treated  with  HBSS (mean 
>250;  P  =  0.007  and P  --  0.008,  respectively).  In  exp.  2,  a  reduction  in  the 
number of pulmonary nodules was again seen at 20,000 (mean =  56) and 100,000 
U  (mean =  9) of IL-2 administered three times daily, compared to mice treated 
with HBSS (mean =  227; P  =  0.07 and P  =  0.01, respectively). 
Reduction  of 10-d pulmonary metastases by IL-2 therapy was  highly repro- 
ducible. The results of 15  consecutive experiments using recombinant  IL-2 to 
treat  10-d metastases are shown in Fig. 4.  1-6,000 U  IL-2 reduced the number 
of pulmonary nodules by 34.6  +  13.3%.  20,000-50,000  U  IL-2 reduced  10-d 
pulmonary metastases by 89.4 +__ 3.9%, and  100,000-200,000  U  IL-2 reduced 
pulmonary metastases by 79.6 _+ 4.7%. 
A  comparison of results using  IL-2 to treat day 3 (Figs.  1 and 2) and day  10 
(Table II and Fig.  4) pulmonary metastases suggested that lower doses of IL-2 
were  more  effective against  day  10  tumors  than  against  day  3  tumors.  Two 
experiments designed to test this observation directly are presented in Table III. 
MCA-105 tumor was injected intravenously on day 0, and beginning either 3 or 
10 d  later, therapy with IL-2 was initiated for 5  d.  All mice were killed on day 
15, and the number of pulmonary tumors was determined. In exp.  1 (Table III), 
control mice (HBSS alone) had a mean of 56 metastases compared to a  mean of 
47  metastases in mice that started  IL-2 treatment at 6,000  U  three times daily 
on day 3 (P =  0.23), and 8 metastases in mice that started IL-2 treatment on day 
10  (P =  0.02).  Similarly, in exp.  2,  control mice had a  mean of 45  metastases 
compared to 54 metastases in mice starting treatment with 20,000 U  IL-2 three ROSENBERG  ET  AL.  1175 
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FIGURE 4.  Results of 15  consecutive experiments evaluating the ability of treatment with 
recombinant I L-2 to reduce the number of 10-day pulmonary metastases. Each dot represents 
a separate experimental measurement in which mice receiving IL-2 were compared to mice 
treated with HBSS alone. 10 d after intravenous injection of MCA-105 sarcoma cells, therapy 
was initiated with varying doses of recombinant IL-2 given intraperitoneally approximately 
every 8 h for 5 d. On days 15-18, mice were killed and pulmonary metastases were counted. 
Doses >20,000  U administered on this schedule were consistently able to reduce the number 
of pulmonary metastases compared to that of control mice. 
TABLE  III 
Treatment of Established (Day 3 and 10) Pulmonary Metastases with 
Recombinant IL-2 
IL-2* 
Mean number of metastases, with treatment 
begun on: 
Day 3  Day 10 
U 
Exp. 1 
0 
6,000 
Exp. 2 
0 
20,000 
56 
47  8 
(P -- 0.23)*  (P =  0.02) 
45 
54  6 
(P --- 0.79)  (P =  0.006) 
* IL-2 was administered in 0.5 ml i.p. three times daily for 5 d, starting 
either 3 or 10 d after tumor injection. 
* Wilcoxon  rank  sum  test  comparing  group  receiving  IL-2  to  group 
receiving no IL-2 (two-sided). 1176  IL-2-INDUCED TUMOR REGRESSION 
TABLE IV 
Treatment of Established (Day 3 and 1  O) Pulmonary Metastases with Recombinant IL-2 
IL-2* 
Mean number of metastases, with treatment begun on: 
Day 3  Day  10 
Irradiated*  Irradiated  Normal mice  Normal mice  mice  mice 
U 
0  >250  >250  172  >250 
100,000  61  >250  7  >250 
(P =  0.003) 0  (P =  0.02) 
* IL-2 was administered in 0.5 ml i.p. three times daily for 5 d, starting either 3 or l0 d after tumor 
injection (separate experiments). 
* 500 rad total body irradiation administered 4 h before tumor cell injection. 
Wilcoxon rank sum test comparing group receiving IL-2 to group receiving no IL-2 (two-sided). 
times daily on day 3 (P =  0.79) and 6 metastases in mice starting treatment on 
day  10  (P =  0.006).  These experiments demonstrated that day  10  metastases 
from the MCA-105 sarcoma were more susceptible to IL-2 therapy than were 
day 3 metastases. 
Antitumor Effect of Recombinant IL-2 Was Eliminated in Preirradiated Mice.  To 
evaluate the role of host factors in the antitumor response mediated by recom- 
binant IL-2, mice received 500 rad total body irradiation from a  a37Cs source, 4 
h before injection of tumor into the tail vein. 3 or 10 d later, therapy was begun 
with  100,000  U  of IL-2,  injected intraperitoneally three  times daily for 5  d 
(Table IV). When treatment was initiated on day 3, IL-2 treatment reduced the 
number of pulmonary metastases in normal, nonirradiated mice from a mean of 
>250 metastases in controls to 61  metastases in IL-2-treated mice (P =  0.003). 
In preirradiated mice, however, treatment with IL-2 resulted in no significant 
reduction  in  the  number of pulmonary metastases  (>250  metastases  in  both 
groups). Similarly, in mice beginning treatment on day 10, a significant effect of 
IL-2 was seen in normal, nonirradiated mice (172  metastases in controls, com- 
pared to 7 in IL-2-treated mice; P =  0.02), although no reduction in pulmonary 
metastases was seen in preirradiated mice (>250 metastases in both groups). This 
inability of recombinant IL-2 to mediate a reduction in the number of metastases 
in  irradiated  mice  was  shown  in  three  additional  experiments,  and  in  two 
experiments  using  thymectomized mice  that  received  1,000  rad  total  body 
irradiation and were reconstituted with T  cell-depleted bone marrow. 
Histologic  Assessment  of the  Regression  of Pulmonary  Metastases  Mediated  by 
Recombinant IL-2.  A histologic assessment of the lungs during the regression of 
pulmonary metastases mediated by IL-2 was conducted by sequentially killing 
mice every other day, beginning at the initiation of IL-2 treatment on day 3 or 
day 10 after intravenous tumor injection. All studies were performed in dupli- 
cate.  Control groups consisted of tumor-bearing mice receiving a  comparable 
volume of HBSS, and of otherwise healthy mice treated with IL-2 alone. All 
tissues were fixed in 10% buffered formalin and processed routinely in paraffin. 
Sections  were  stained  with  hematoxylin and  eosin.  Histologic interpretations 
were made by a pathologist (C. Reichert). ROSENBERG  ET  AL.  1177 
FIGURE 5.  Histologic  appearance of pulmonary metastases  from the MCA-105 sarcoma  (left). 
Typical appearance of a 3-d-old, untreated pulmonary metastasis. Growth of hematogenously 
disseminated  tumor cells  (arrow) has resulted in expansion  of an alveolar  septum. (Hematoxylin 
and eosin, original magnification x860). 10-d-old, untreated pulmonary metastasis located 
within a  dilated perivenular lymphatic channel (right).  (Hematoxylin and  eosin, original 
magnification  x 130). 
3 d after tail vein injection of tumor cells, numerous micrometastases, ranging 
up  to  10  tumor cell  diameters,  were  detected in  necropsy specimens of lung. 
Most of the tumor cell aggregates were located within alveolar septae; many had 
ruptured into the alveolar air spaces. The characteristic appearance of one such 
metastasis is shown in Fig. 5, left.  In those experiments where IL-2 immunother- 
apy was delayed until 10 d after tumor injection, the tumor nodules were grossly 
visible, and, microscopically, ranged up to 50 tumor cell diameters. At this time 
most of the tumor nodules were  located within perivenular and peribronchial 
lymphatics, and subpleural  spaces  (Fig.  5,  right).  By 4  d  after the  thrice  daily 
intraperitoneal injections of 100,000  U  IL-2, many activated lymphocytes were 
noted within the lungs, primarily within lymphatic channels of the interlobular 
pulmonary septae (Fig. 6, left).  Cytologically, these lymphocytes had larger nuclei, 
more  irregular  nuclear  contours,  and  more  open  chromatin  patterns  (Fig.  6, 
right)  than typical small, mature lymphocytes. Mitoses were frequent among IL- 
2 stimulated lymphocytes. After 6 d  of IL-2 administration, numerous activated 
lymphocytes were seen circulating within alveolar capillaries (Fig.  7),  as well as 1178  IL-2-INDUCED  TUMOR  REGRESSION 
FIGURE 6,  Mice repeatedly stimulated by intraperitoneal injections of IL-2 show a marked 
accumulation of activated lymphocytes, primarily in a perivenular lymphatic distribution (left). 
(Hematoxylin and eosin, original magnification × 130).  High-power view of activated lympho- 
cytes in  a  dialated  perivenular lymphatic within  the  lung of an  IL-2-treated  mouse  (right). 
Some of the lympbocytes are seen within the lumen of a pulmonary vein (V). (Hematoxylin 
and eosin, original magnification ×860). 
within multiple parenchymal organs. Overall numbers of lymphocytes appeared 
to be increased over non-tumor bearing controls that received IL-2. 
With respect to the histologic appearance of tumor in IL-2-treated vs. control 
mice, the primary differences were in the number, size, and extent of lymphocytic 
infiltration of the tumor metastases (Fig. 8). Micrometastases contained lympho- 
cytes within the centers of the tumor masses as well as at the perimeters, with 
far greater numbers of lymphocytes present in the IL-2-treated mice. Increasing 
numbers of  activated lymphocytes  were apparent in the tumor nodules as therapy 
with  IL-2  proceeded  and  lesions  regressed  (Fig.  8,  right).  Those  few  tumor 
nodules that  failed to regress  in  IL-2-treated mice showed a  predilection  for 
subpleural localization, but were otherwise histologically indistinguishable from 
untreated controls. 
Treatment  of  Subcutaneous  Sarcoma  by  Recombinant  IL-2.  Two  treatment 
models were studied to evaluate the ability of recombinant IL-2 treatment to 
affect the growth of subcutaneous tumors. First, 2 ×  104 MCA-105 sarcoma cells 
were injected subcutaneously, and 3 d later IL-2 therapy was given for ~5 d. No ROSENBERG  ET  AL,  1179 
FIGURE 7.  Appearance of lung parenchyma 6 d after the initiation of IL-2 immunotherapy 
(right).  Note the diffuse lymphoid infiltrate. A normal mouse lung is provided for comparison 
(left).  (Hematoxylin  and eosin, original magnification  ×220). 
palpable tumor was evident at the onset of therapy. A characteristic experiment 
is shown in Fig. 9. The latent period of tumor appearance, defined as the time 
to development of palpable tumor in more than half of the mice, was prolonged 
by 16 d (P =  0.02) by treatment with 170,000 U  IL-2 i.p. three times a day. The 
results of four consecutive experiments are shown in Table V. The latent period 
was  prolonged  from  ~10  d  to  19-35  d  in  the  four  experiments.  In  each 
experiment, all animals treated with HBSS developed tumors, while 17-40%  of 
mice  treated  with  recombinant  IL-2  never  developed  tumors,  over  a  2-too 
observation period. 
Recombinant IL-2 could also be used to successfully treat palpable tumors. By 
10  d  after tumor cell injection, tumors were palpable,  with a  diameter of 2-4 
mm. Initiation of IL-2 therapy at this time caused a  dramatic reduction in  the 
growth rate of tumors, as well as the disappearance of tumors in some animals. 
A  representative  experiment  is  shown  in  Fig.  10.  In  this  experiment,  mice 
received 200,000  U  i.p.  thrice daily for  13  d,  although occasional doses were 
skipped  if mice appeared  lethargic.  Tumor  grew progressively in  all  six  mice 
treated with HBSS alone. In mice receiving IL-2, tumor growth was substantially 
inhibited in all six mice, and tumor regressed completely in three mice. 1180  IL-2-INDUCED  TUMOR  REGRESSION 
FIGURE 8.  Appearance of an 18-d-old pulmonary metastasis from an untreated mouse (left). 
(Hematoxylin and eosin, original magnification x 170). Appearance of an 18-d-old pulmonary 
metastasis from a mouse treated with IL-2 (right).  Note the increased numbers of lymphocytes 
associated with the spindle-shaped sarcoma cells. (Hematoxylin and eosin, original magnifica- 
tion x 170). 
Discussion 
IL-2  is  a  lymphokine,  with  a  mol  wt  of-15,000,  that  is  produced  by  T 
lymphoid cells  (11).  In  vitro,  IL-2  has  a  broad  range  of immunoregulatory 
activities  that  appear  to  stem  from  the  ability  of  IL-2  to  expand  selected 
subpopulations of T  cells that bear IL-2 receptors (12). The systemic administra- 
tion of IL-2 in vivo also has a broad range of immunologic effects, including the 
induction of specific T  helper cells, cytotoxic cells, and autoantibody production 
in  nude  mice  (13-15),  and  the  enhancement of the  restoration  of immune 
function in irradiated rats (16) or in mice treated with cyclophosphamide (17). 
System injection of IL-2 is capable of  specifically enhancing alloimmune responses 
in either normal or primed (18,  19) mice, and has been shown to enhance the 
antitumor activity of adoptively transferred, expanded, IL-2-dependent, specifi- 
cally immune lymphocytes (20, 21). 
In  1980,  we first noted an unusual effect of IL-2 on resting lymphoid popu- 
lations in  vitro.  Incubation of either murine splenocytes or human peripheral 
blood lymphocytes from normal or tumor-bearing hosts in iymphokine prepa- 
rations containing IL-2 resulted in the generation of lymphoid cells capable of ROSENBERG  ET  AL.  1181 
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FIGURE 9.  Treatment with recombinant IL-2 inhibited growth of day 3 subcutaneous tumor. 
2  ×  104  MCA-105 sarcoma cells were injected subcutaneously, and  3  d  later therapy was 
initiated with  170,000  U  recombinant IL-2 given intraperitoneally approximately every 8 h 
for 5 d. Mean tumor size (the product of perpendicular diameters) is presented in the upper 
panel, and time of tumor appearance is presented in the lower panel. The black bar indicates 
the interval of treatment with IL-2.  A  significant delay in  tumor appearance was seen in 
animals treated with recombinant IL-2 (P = 0.02). 
TABLE  V 
Treatment of lntradermal Tumor with Recombinant IL-2 
Duration of  Exp.  IL-2* 
treatment 
Latent period* 
Final tumor incidence 
(number of mice with tu- 
mor/total)  j 
Recombi-  Recombi-  HBSS  HBSS  nant IL-2  nant IL-2 
U  d  d 
]  100,000  3-8  ll  ]9  5/5  3/5 
2  100,000  3-8  10  26  6/6  5/6 
3  100,000  3-8  10  21  6/6  5/6 
4  200,000  3-6  l0  35  6/6  3/4 
400,000  3-6  --  35  --  3/5 
* IL-2 was administered in 0.5 ml i.p. three times daily. 
* Latent period was defined as the time to development of palpable tumor in more than half of mice. 
0 Mice observed for >2 mo. 1182  IL-2-1NDUCED  TUMOR  REGRESSION 
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FIGURE  I 0.  Treatment of established subcutaneous tumor with recombinant IL-2. l0 d after 
the  injection of 2  x  I04  MCA-105  sarcoma  cells,  palpable  nodules were  present in  the 
subcutaneous area. At this time therapy was initiated with 200,000  U  of recombinant IL-2 
administered intraperitoneally approximately every 8 h for 13 d. The black bar indicates the 
interval of treatment with  IL-2.  Toxicity due to IL-2 administration necessitated skipping 
occasional doses. Each line represents the growth of tumor in an individual mouse. Whereas 
tumor grew progressively in all control mice injected with HBSS alone, all mice receiving IL- 
2 exhibited decreased tumor growth, and tumor disappeared completely in three mice. 
lysing fresh autologous or syngeneic tumor cells in short term chromium-release 
assays  (1-4).  We  have  subsequently  characterized  these  lytic  cells,  and  have 
termed them LAK cells (4,  22).  In both mouse and human,  LAK cells are lytic 
for a broad range of autologous, syngeneic, and allogeneic fresh tumor cells, but 
they do not  lyse fresh  normal  cells,  such as peripheral  blood lymphocytes, or 
lung or liver cells. This broad lytic specificity has been seen both in direct lytic 
assays, as well as by using cold-target inhibition techniques.  LAK cells appear to 
represent a lytic system distinct from that of natural killer (NK) cells and cytotoxic 
T  lymphoid cells, although  this  is an  area  of some controversy.  Precursors of 
LAK cells in humans are negative for characteristic markers of NK cells, such as 
OKM1  and  Leu-7, and are negative for T  cell markers such as Leu-1, OKT3, 
OKT4, and OKT8. The mature LAK effector cell generated following incuba- 
tion in I L-2, however, bears many of the characteristic markers of classic cytolytic 
T  lymphoid cells. In humans,  LAK effector cells are OKM 1-, OKT3÷,4-,8 +, and 
are Leu-1 + (22, 23). In the mouse, LAK effector cells are Thy-1 +, Lyt-l-,2 + (4). 
IL-2 alone appears to be sufficient for the induction of LAK cells, because highly 
purified  IL-2  preparations  obtained  from  recombinant  E.  coli  are  capable  of 
generating both human and murine LAK cells (5). The relationship of LAK cells 
to other forms of anomalous cytotoxicity induced in vitro by a variety of other 
techniques,  such as  incubation  with  lectins  (24),  pooled allogeneic stimulation 
(25-27),  or  incubation  in  heterologaus  serum  (28),  is  unclear,  although  it  is 
possible that IL-2 stimulation represents a final common pathway for generating 
these lytic activities in lymphocytes in vitro. ROSENBERG  ET  AL.  1183 
Because of the high  degree of lytic specificity of LAK cells for flesh tumor, 
and due to the relative ease of generation of LAK cells, we explored the ability 
of LAK  cells  to  mediate  antitumor  effects when  injected  in  vivo.  We  have 
previously  demonstrated  (6)  that  the  injection  of LAK  cells  was  capable  of 
mediating  the regression  of established pulmonary  metastases from B16 mela- 
noma that  were induced either by the intravenous  injection of B16 melanoma 
cells,  or from  spontaneous  metastases of B16 melanoma  growing  in  the  hind 
limb. More recently (7), we have demonstrated that the systemic administration 
of LAK cells to mice bearing a variety of sarcomas resulted in the regression of 
established day 3 and day 10 pulmonary metastases, when LAK cells were injected 
in combination with the systemic administration  of recombinant IL-2. 
The recent availability of recombinant-derived  IL-2 resulting from the inser- 
tion into E.  coli of the gene coding for human IL-2 has provided large amounts 
of highly purified IL-2 for in vivo studies (5). Preliminary experiments, in which 
mice received continuous infusions of recombinant IL-2 either intraperitoneally 
or subcutaneously,  using an osmotic pump,  indicated  that  LAK cells could be 
generated  in  the  spleen  of mice in  vivo (29).  The  in  vivo antitumor  effect of 
LAK  cells  in  combination  with  recombinant  IL-2,  and  the  suggestion  that 
systemically administered  recombinant  IL-2  generated  LAK cells in vivo have 
led us to explore the ability of high-dose  IL-2 administration  alone to mediate 
the regression of established syngeneic tumors. 
Large  doses of IL-2  were required  in  these studies.  We previously (29,  30) 
showed that the serum half-life of natural and recombinant IL-2 in mice was -2 
min  after  intravenous  injection  (29,  30).  The  primary  mechanism  for  IL-2 
clearance appeared to be metabolism in the renal tubules, since clamping of both 
renal pedicles extended the half-life of IL-2 ~40-fold, while ureteral ligation did 
not significantly change the half life of IL-2. Further, we were not able to isolate 
IL-2 from urine of mice given high doses of this material (30). 
In these studies, we have demonstrated that the intraperitoneal administration 
of high  doses of recombinant  IL-2 was capable of generating  LAK cells in the 
spleens of mice. Intraperitoneal  administration  of 100,000 U  recombinant IL-2 
approximately every 8  h  resulted in the generation  of significant  levels of lytic 
activity against a variety of MCA-induced sarcomas in chromium-release assays. 
Using this dosage regimen,  sequential measurement of serum levels of IL-2 in 
these  mice  revealed  IL-2  levels  of 3,000-4,000  U/ml  in  serum  for  the  first 
several hours after intraperitoneal  injection, followed by a drop in titer to -5- 
10 U/ml in serum by the time the next dose was given (data not shown). These 
findings are in accord with our previous observations (29,  30) concerning  the 
absorption of IL-2 administered intraperitoneally. 
Administration  of high  doses of recombinant  IL-2 consistently mediated the 
regression  of established  tumor  in  both  lungs and  subcutaneous areas.  In  the 
treatment of mice 3 d after tumor injection, at a time when pulmonary metastases 
were firmly established  in  the  lung,  ~100,000  U  IL-2 given  intraperitoneally 
thrice daily was required to mediate the inhibition of pulmonary metastases from 
the MCA-105  tumor.  At this  IL-2 dose, significant  inhibition  of the syngeneic 
MCA-106  sarcoma  as  well  as  of the  syngeneic  B16  melanoma  was also seen. 
Administration  of  3,000-8,000  U  IL-2  had  little  effect  on  3-d  pulmonary 1184  IL-2-INDUCED TUMOR REGRESSION 
metastases,  and  in  only  occasional  experiments  did  20,000-50,000  U  IL-2 
injected intraperitoneally  three times a day mediate antitumor effects. At doses 
of  100,000  U  IL-2  intraperitoneally  three  times  daily,  >70%  reduction  of 
pulmonary metastases was seen in 9 of 10 experiments. 
Somewhat  surprisingly,  pulmonary  metastases  established  10  d  before  the 
onset of therapy appeared to be more sensitive to treatment with IL-2. By 10 d 
after intravenous injection, the tumor nodules were grossly visible in the lung, 
and were comprised of many hundreds  of tumor cells. 20,000  U  recombinant 
IL-2  intraperitoneally  three  times daily was capable of substantially  inhibiting 
pulmonary metastases in this 10-d tumor model; dosages from 20,000 to 50,000 
U  IL-2 showed >70% reduction of pulmonary metastases in five of five experi- 
ments.  In two experiments,  a  direct comparison of the treatment of day 3 and 
day 10 metastases with relatively low doses of recombinant IL-2 confirmed this 
increased sensitivity of larger metastases to the effects of recombinant I L-2. Since 
mice that were treated  10 d after tumor injection had grossly visible metastases 
on the lung surface that could be counted, these experiments indicated that IL- 
2  not only inhibited  tumor growth,  but was capable of actually mediating  the 
regression of established metastases. This phenomenon was also apparent in the 
treatment  of subcutaneous  sarcomas.  The  treatment  of  mice  3  d  after  the 
subcutaneous  injection  of MCA-105  sarcoma  in  the  belly  skin  resulted  in  a 
substantial increase in the latency period of tumors, and cured 15-40% of mice. 
When treatment was instituted  10 d after injection of subcutaneous tumor, at a 
time when tumor was easily palpable, tumor growth was substantially inhibited 
in all mice, and in ~50%  of mice, tumor regression was noted, with long term 
cure of these mice. Mice cured by these means were then capable of resisting a 
subsequent tumor challenge (data not shown). 
The mechanism by which IL-2 mediates the regression of established tumor is 
not clear. Although IL-2 is capable of mediating the generation of LAK cells in 
vivo, we have no direct evidence that  these  LAK cells are  responsible for the 
antitumor  effects seen. A  possible mechanism of the antitumor  activity of IL-2 
involves the in vivo generation  of LAK cells, either in lymphocytes infiltrating 
the  tumor,  or  at  other  sites,  with  subsequent  migration  to  the  tumor.  The 
increased  number  of lymphocytes in  larger,  compared  to  smaller,  pulmonary 
metastases may explain the increased sensitivity of larger tumors to IL-2 admin- 
istration.  It  is  quite  clear,  however,  that  the  antitumor  effects  of  IL-2  are 
eliminated if mice received a prior dose of 500 rad total body irradiation.  The 
inability  of IL-2 to mediate  antitumor  effects in  these  irradiated  mice implies 
that  the  IL-2 is not directly mediating  tumor regression,  but,  rather,  is acting 
through a radiosensitive host component. 
Further  evidence supporting the role of LAK cells in the rejection of estab- 
lished tumor comes from a histologic assessment of regressing pulmonary metas- 
tases. Within  2 d  after the injection of IL-2 into mice bearing  10-d pulmonary 
metastases, lymphocytes that look activated are seen infiltrating the periphery of 
the tumor.  With progressive treatment,  activated lymphocytes are seen infiltra- 
ting  throughout  resolving  tumor.  By 6-8  d  after  the  onset of therapy,  many 
tumor nodules had undergone complete regression. Activated lymphocytes have 
been  noted  not  only in  the  lung,  but in  the  liver,  spleen, and  kidney as well. ROSENBERG  ET  AL.  1185 
While we have as yet no evidence that these activated lymphocytes have lympho- 
kine-activated killing activity, an attractive hypothesis is that the systemic admin- 
istration of IL-2 is leading to the generation of LAK cells in vivo from precursor 
lymphocytes within the growing tumor, which then mediate tumor destruction. 
Larger tumors may have an increased relative number of infiltrating  lymphoid 
cells, and this may account for the increased sensitivity of day 10 tumors to IL- 
2 therapy, compared to the sensitivity of day 3 tumors. 
Other  possible mechanisms  for the antitumor  effect of IL-2 should be men- 
tioned. It has been shown (20, 21) that IL-2 is capable of enhancing the antitumor 
activity  of specifically immune  cells.  If small  numbers  of specifically immune 
lymphoid cells are present in growing tumor nodules, then IL-2 may be capable 
of expanding the numbers of these cells in vivo. In vitro stimulation of lymphoid 
cells with IL-2 leads to the secretion of interferon, and it is likely that the systemic 
administration  of IL-2 leads to the secretion of a  variety of other lymphokines 
from T  lymphoid cells in vivo (31-33). In our initial clinical trials of recombinant 
IL-2 administration  to humans, circulating levels of interferon have been noted. 
It is thus possible that IL-2 mediates antitumor effects, not by the induction of 
LAK cells, but rather by its ability to mediate the secretion of other lymphokines 
by T  lymphoid cells. 
The antitumor effects of IL-2 we have noted in vivo and the ready availability 
of recombinant  IL-2  makes  treatment  with  this  lymphokine  an  attractive  ap- 
proach to the treatment of human cancer. We have recently completed phase I 
clinical  studies of the administration  of natural  and recombinant  IL-2 by both 
continuous  infusion  and  bolus  injection  into  humans,  and  we  are  currently 
initiating trials to explore the antitumor efficacy of maximally tolerated doses of 
recombinant IL-2 in humans with advanced cancer. The use of recombinant IL- 
2 directly, as well as in conjunction with LAK cells, is an attractive new approach 
to the treatment of human cancer that warrants active investigation. 
Summary 
Incubation of resting lymphoid cells with recombinant interleukin  2 (IL-2) in 
vitro leads to the generation  of lymphokine activated killer (LAK) cells capable 
of lysing fresh  tumor  cell  suspensions  in  short-term  chromium-release  assays. 
Our previous studies (7) have demonstrated that the injection of LAK cells plus 
low doses of recombinant IL-2 were capable of inhibiting the growth of pulmo- 
nary metastases. We have now explored the ability of high doses of recombinant 
IL-2, administered  systemically, to generate  LAK cells in vivo, and to mediate 
antitumor  effects directly.  Administration  of increasing  doses of recombinant 
IL-2 intraperitoneally  resulted in the generation of LAK cells in the spleens of 
recipient mice. Doses of 100,000 U  recombinant IL-2 administered intraperito- 
neally approximately every 8 h  for 5 d  were capable of dramatically  inhibiting 
established 3-d pulmonary metastases from the MCA-105 and MCA-106 synge- 
neic sarcomas and the syngeneic B 16 melanoma in C57BL/6 mice. Grossly visible 
metastases  present  at  10  d  after  tumor  injection  also  underwent  regression 
following IL-2 therapy. Surprisingly, established 10 d pulmonary metastases were 
more susceptible to  the  effects of IL-2  than  were the  smaller  3  d  pulmonary 
metastases. All antitumor  effects of the systemic administration  of recombinant 1186  IL-2-INDUCED TUMOR  REGRESSION 
IL-2 were eliminated if mice received prior treatment with 500 rad total body 
irradiation.  The  administration  of high  doses  of recombinant  IL-2  was  also 
capable of inhibiting  the growth of 3-d established  subcutaneous tumors from 
the MCA- 105 sarcoma, and of mediating the inhibition of growth and regression 
of established palpable subcutaneous  MCA-105  sarcomas.  Lymphocytes, which 
appeared morphologically to be activated, were present at the site of regressing 
tumor, and it appears that the mechanism of the antitumor effect of recombinant 
IL-2 administered systemically is via the generation of LAK cells in vivo, although 
this  hypothesis remains  to be proven.  The ready availability of high  doses  of 
recombinant human  IL-2, and  the demonstration  of antitumor effects seen in 
animal models have led us to the initiation of the clinical trials of recombinant 
IL-2 in humans. 
Received for publication  21 November  1984 and in revised form 5 February  1985. 
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